文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

来那度胺联合或不联合促红细胞生成素刺激剂治疗骨髓增生异常综合征的疗效决定因素:HOVON89试验

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
PubMed 文献 · Leukemia · 2024-01-31

HOVON89是一项随机II期研究,纳入低危/中危-1(IPSS)骨髓增生异常综合征患者,比较来那度胺单药(A组)与联合ESA/G-CSF(B组)的疗效与安全性,主要终点为红系反应(HI-E)。最终评估184例患者,A组和B组HI-E率分别为39%和41%,中位至HI-E时间均为3.2个月,中位HI-E持续时间9.8个月;非del(5q)患者HI-E率显著低于del(5q)患者(32% vs 80%)。

要点

  • 来那度胺在非del(5q)和del(5q)骨髓增生异常综合征中均诱导红系反应,联合ESA/G-CSF未增加疗效。
  • 非del(5q)患者红系反应率显著低于del(5q)患者(32% vs 80%)。
  • 高骨髓淋巴细胞及祖B细胞比例、低突变数、无环形铁粒幼红细胞及SF3B1突变可预测红系反应。

核心结论

  • 来那度胺在非del(5q)和del(5q)低危/中危-1骨髓增生异常综合征患者中诱导红系反应,联合ESA/G-CSF未产生额外效应。
  • 所识别的反应预测因素可能指导精准医学时代来那度胺在较低危骨髓增生异常综合征中的应用。

研究设计与样本

  • 随机II期研究(HOVON89,EudraCT 2008-002195-10),纳入低危/中危-1(IPSS)骨髓增生异常综合征患者184例。
  • A组接受来那度胺单药,B组接受来那度胺联合ESA/G-CSF;B组4周期后无红系反应者加用ESA,第9周期仍无红系反应者加用G-CSF。
  • 采用流式细胞术和二代测序识别反应预测因素;主要终点为红系反应(HI-E)。

主要发现

  • A组和B组红系反应率分别为39%和41%;两组中位至红系反应时间均为3.2个月,中位红系反应持续时间均为9.8个月。
  • 非del(5q)患者红系反应率显著低于del(5q)患者:32% vs 80%。
  • 第24周输血非依赖率在非del(5q)与del(5q)患者中分别为16% vs 67%,两组间相似。
  • 除del(5q)外,高骨髓淋巴细胞及祖B细胞百分比、低突变数、无环形铁粒幼红细胞及SF3B1突变预测红系反应。
  • 最终评估184例患者中,84%为非del(5q),16%为孤立del(5q);中位随访70.7个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. van de Loosdrecht AA, Cremers EMP, Alhan C, et al. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial. Leukemia. 2024. PMID: 38297135. doi:10.1038/s41375-024-02161-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。